Development of the Mycobacterium bovis BCG vaccine: Review of the historical and biochemical evidence for a genealogioal tree

Tubercle and Lung Disease

Volumn 79, Issue 4, 1999, Pages 243-250

  Oettinger, T ^a   Jorgensen M ^a   Ladefoged, A ^a   Haslov K ^a   Andersen, P ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

BCG VACCINATION; DRUG DEVELOPMENT; GENE LOSS; GENEALOGY; HISTORY OF MEDICINE; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; REVIEW; VIRULENCE;

EID: 0032879222     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1054/tuld.1999.0206     Document Type: Article

References (110)

1. Frappier, A, Panisset, M, La Souche du BCG. Monographie de l'Institut de Microbiologie et d'Hygiène de l'Université de Montréal. Montréal: Thérien, 1957.
2. Weill-Hallé B, Turpin R. Premiers essais de vaccination antituberculeuse de l'enfant par le Bacille Calmette-Guérin (BCG). Bull Mem Soc Med l'Hosp de Paris. 49:1925;1589-1601.
3. Frappier A, Panisset M. Present knowledge and recent personal investigation on BCG daughter-strains. Extrait de la Revue Canadienne de Biologie. 19:1960;449-466.
4. Osborn T W. Studies 'in vitro' of BCG daughter strains. Intl Sym BCG Vac. 17:1971;125-132.
5. Osborn T W. Changes in BCG strains. Tubercle. 63:1983;1-13.
6. Bunch-Christensen K, Ladefoged A, Guld J. The virulence of some strains of BCG for golden hamsters. Bull WHO. 39:1968;821-828.
7. Dubos R J, Pierce C H. Differential characteristics in vitro and in vivo of several substrains of BCG. I. Multiplication and survival in vitro. Am Rev Tuberc. 74:1956;655-666.
8. Dubos R J, Pierce C H. Differential characteristics in vitro and in vivo of several substrains of BCG. II. Morphological characteristics in vitro and in vivo. Am Rev Tuberc. 74:1956;667-682.
9. Dubos R J, Pierce C H, Schaeffer W B. Differential characteristics in vitro and in vivo of several substrains of BCG. III. Multiplication and survival in vivo. Am Rev Tuberc. 74:1956;683-698.
10. Dubos R J, Pierce C H. Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness. Am Rev Tuberc. 74:1956;699-714.
11. Jacox R F, Meade G M. Variation in the duration of tuberculin skin sensitivity produced by two strains of BCG. Am Rev Tuberc. 60:1949;541-546.
12. Jespersen, A, The potency of BCG vaccines determined on animals. Doctoral dissertation. Copenhagen, Denmark 1971.
13. Vallishayee R S, Shashidhara A N, Bunch-Christiansen K, Guld J. Tuberculin sensitivity and skin lesions in children after vaccination with 11 different BCG strains. Bull WHO. 51:1974;489-494.
14. Bunch-Christensen K. Evaluation of BCG vaccines in children, the effect of strain and dose. J Biol Stand. 5:1977;159-164.
15. Ladefoged A, Bunch Christensen K, Guld J. The protective effect in bank voles of some strains of BCG. Bull WHO. 43:1970;71-90.
16. 2(primary and secondary seed-lots). Bull Inst Pasteur. 83:1983;281-288.
17. Milstein, J, B, Gibson, J, J, Quality control of BCG vaccines by the World Health Organization: a review of factors that may influence vaccine effectiveness and safety. WHO/EPI/Gen/89.1, World Health Organization, Geneva, 1989.
18. Minnikin D E, Parlett J H, Magnusson M, Ridell M, Lind A. Mycolic acid patterns of representatives of Mycobacterium bovis BCG. J General Micribiol. 130:1984;2733-2736.
19. Hyge T E. The Efficacy of BCG-vaccination: epidemic of tuberculosis in a state school, with an observation period of 12 years. Acta Tub Scand. 32:1956;89-107.
20. Indian J Med Res. 72:1980;1-74.
21. Ponninghaus J M, Fine P M, Sterne J A C. Efficacy of BCG against leprosy and tuberculosis in northern Malawi. Lancet. 339:1992;636-639.
22. Lancet. 348:1996;17-24.
23. Oettinger T, Andersen Å B. Cloning and B-cell epitope mapping of MPT64 from Mycobacterium tuberculosis H37Rv. Infect Immun. 62:1994;2058-2064.
24. Harboe M, Oettinger T, Wiker H G, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 64:1996;16-22.
25. Mahairas G G, Sabo P J, Hickey M J, Singh D C, Stover C K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bact. 178:1996;1274-1282.
26. Guérin C. The history of BCG. Chapter 3. Rosenthal S R. BCG vaccine: Tuberculosis-Cancer. 1980;35-43 PSG Publishing Company, Littleton.
27. Guérin C. Le BCG et la prévention de la tuberculose. Rev Atomes. 27:1948;183-188.
28. Guérin C. Prophylaxe gegen Tuberculose Infectionen bei Rindern mittels BCG. Wien Klin Wschr. 21:1928;731-735.
29. Gheorghiu M. Antituberculosis BCG vaccine: lessons from the past. Plothin S, Fantini B. Vaccinia, vaccination and vaccinology: Jenner, Pasteur and their successors. 1996;87-94.
30. ie, Paris.
31. Calmette A. La vaccination preventive de la tuberculose par BCG (Bacille Calmette-Guérin). Ann Inst Pasteur. 12:1928;1-58.
32. Frappier A. Le vaccin antituberculeux BCG, decouverte - son innocuite. Revue Trimestrielle Canadienne. 1935.
33. Bretey J. Historique de la découverte du BCG. International Symposium on BCG Vaccine, Frankfurt (Main). Symp Series Immunobiol Standard. 17:1971;103-108.
34. Kumabe H. Dried BCG vaccine in Japan. Bull IUAT. 27:1957;92-99.
35. van Deinse F, Sénéchal F. BCG on Sauton's medium. Effect of a long series of subcultures on the morphological and biological properties of BCG cultures. Bull WHO. 2:1950;347-354.
36. Premier Congrès International du BCG, Institut Pasteur Paris, 1948, 352p.
37. Ladefoged A, Bunch Christensen K, Guld J. Tuberculin sensitivity in guinea pigs after vaccination with varying doses of BCG of 12 different strains. Bull WHO. 53:1976;435-443.
38. Jespersen A. The virulence of various strains of BCG determined on the golden hamster. Acta Tuberc et Pneumologica Scand. 44:1964;222-249.
39. Mande R. The protection afforded by vaccination. Chapter 6. BCG vaccination. 1968;Dawsons of Pall Mall, London. p. 198-224.
40. Guld J. BCG as an immunizing agent. Barclay W R, Koch-Weser D, Wolinsky E, Chamberlaynes E C. Status of immunization in tuberculosis in 1971. Fogarty International Center Proceeding No. 14. 1971;72-68 DHEW Publication No. (NIH), Washington.
41. Lind A. The Swedish substrain of BCG. Series Immunobiol Stand. 17:1971;115-116.
42. Crispen R. History of BCG and its substrains. EORTEC Genitourinary Group Monograph 6: BCG. 1989;. p. 35-50.
43. De Jager R, Guinan P, Lamm D. Long-term complete remission in bladder carcinoma in situ with intravesical Tice Bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology. 38:1991;507-513.
44. Assis A. À propos des fondemonts et de la pratique de la vaccination B.C.G. au Brésil. Poumon Coeur. 12:1956;935-940.
45. Watanabé Y, Harajawa J, Ono I. Vaccinations BCG au Japon. Calmette A. Vaccination preventive de la tuberculose de l'hommes et des animaux par le BCG. 1932;221-226 Masson et Cie, Paris.
46. WHO-document WHO/BS/802.65.
47. Bøe J. Variations in the virulence of BCG. Acta Tuberc Scand. 22:1947;125-133.
48. Romanus V, Fasth A, Tordai P, Wiholm B E. Adverse reactions in healthy and immunocompromised children under six years of age with the Danish BCG vaccine, strain Copenhagen 1331: Implications for the vaccination policy in Sweden. Acta Paediatr. 82:1993;1043-1052.
49. Jensen K A, Mörch J R, Ørskov J. Recherches sur la virulence du Bacille Calmette-Guérin. Ann Inst Pasteur. 6:1929;785-798.
50. Jensen K A. Nye retningslinier for tuberkuloseprofylaksen eksperimentelt og epidemiologisk belyst. Ugeskr f Laeger. 40:1934;1090-1097.
51. Jensen K A. Practice of the Calmette vaccination. Acta Tuberc Scand. 20:1946;1-45.
52. Holm J. BCG vaccination in Denmark. Pub Health Rep. 61:1946;1298-1315.
53. Bunch-Christensen K. BCG-vaccinen 1927-1983. Rüdiger M. Statens Seruminstitut 90 år. 1992;59-67 Statens Seruminstitut, Copenhagen.
54. Nyboe, J, Bunch-Christensen, K, Progress report for assays of BCG vaccines 1965/66. Danish Tuberculosis Index, Svanemøllevej 25, 2100 Copenhagen Ø. Internal Document.
55. Nyboe, J, Bunch-Christensen, K, Assays in man of different BCG products. 1966/67. Danish Tuberculosis Index and Statens Serum Institut. Internal Document.
56. Siebenmann C O, Barbara C. Quantitative evaluation of the effectiveness of Connaught freeze-dried BCG vaccine in mice and guinea pigs. Bull WHO. 51:1974;283-289.
57. Bunch-Christensen K, Ladefoged A, Guld J. The virulence of some strains of BCG for golden hamsters. Bull WHO. 43:1970;65-70.
58. Smith D, Harding G, Chan J, Edwards M, Hank J, Muller D, Sobhi F. Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs. J Biol Stand. 7:1979;179-197.
59. Li H, Ulstrup J C, Jonassen T Ø, Melby K, Nagai S, Harboe M. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect Immun. 61:1993;1730-1734.
60. Sørensen A L, Nagai S, Houen G, Andersen P, Andersen Å B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun. 63:1995;1710-1717.
61. Cole S T, Brosh R, Parkhill J. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:1998;537-544.
62. Kamerbeek J, Schouls L, Kolk A. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 35:1997;907-914.
63. Collins D M, Erasmuson S K, Stephens D M, Yates G F, De Lisle G W. DNA fingerprinting of Mycobacterium bovis strains by restriction fragment analysis and hybridization with insertion elements IS1081 and IS6110. J Clin Microbiol. 31:1993;1143-1147.
64. Fomukong N G, Dale J W, Osborn T W, Grange J M. Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. J Appl Bact. 72:1992;126-133.
65. Klausen J, Magnusson M, Andersen Å B, Koch C. Characterization of purified protein derivate of tuberculin by use of monoclonal antibodies: isolation of a delayed-type hypersensitivity reactive component from Mycobacterium tuberculosis culture filtrate. Scand J Immunol. 40:1994;345-349.
66. Andersen Å B, Ljungqvist L, Hasløv K, Bentzon M W. MPB64 possesses 'tuberculosis - complex' - specific B- and T-cell epitopes. Scand J Immunol. 34:1991;365-372.
67. Hasløv K, Andersen Å B, Bentzon M W. Biological activity in sensitized guinea pigs of MPB70, a protein specific for some strains of Mycobacterium bovis BCG. Scand J Immunol. 26:1987;445-454.
68. Ljungquist L, Worsaae A, Heron I. Antibody responses against Mycobacterium tuberculosis in 11 strains of inbred mice: novel monoclonal antibody specificity's generated by fusion's, using spleens from BALB.B10 and CBA/J mice. Infect Immun. 56:1988;1994-1998.
69. Harboe M, Nagai S. MPB70, a unique antigen of Mycobacterium bovis BCG. Am Rev Respir Dis. 129:1984;444-452.
70. Andersen Å B, Andersen P, Ljungquist L. Structure and function of a 40,000-molecular-weight protein antigen of Mycobacterium tuberculosis. Infect Immun. 60:1992;2317-2323.
71. Berthet F X, Rasmussen P B, Rosenkrands I, Andersen P, Gicquel B A. Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-weight culture filtrate protein (CFP-10). Microbiol. 144:1998;3195-3203.
72. Kayne G G. BCG vaccination in Western Europe. Am Rev Tuberc. XXXIV:1936;10-42.
73. Weldingh K, Rosenkrands I, Jacobsen S, Rasmussen P B, Elhay M, Andersen P. 2DE for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun. 66:1998;3492-3500.
74. Matsuo T, Matsumoto S, Ohara N, Kitaura H, Mizuno A, Yamada T. Differential transcription of MPB70 genes in two major groups of Mycobacterium bovis BCG substrains. Microbiol. 141:1995;1601-1607.
75. Abou-Zeid C, Rook G A W, Minnikin D E, Parlett J H, Osborn T W, Grange J M. Effect of the method of preparation of Bacille Calmette Guérin (BCG) vaccine on the properties of four daughter strains. J Appl Bact. 63:1987;3212-3214.
76. Watson E A, McIntosh C, Konst H. Researches on Bacillus-Calmette-Guérin and experimental vaccination against bovine tuberculosis. J Am Vet M A. LXXIII:1928;799-816.
77. King M, Park W H, Fellow A. Effect of Calmette's BCG vaccine on experimental animals. Am J Pub Hlth. 19:1929;179-182.
78. Park W H, Kereszturi C, Mishulow L. Effect of vaccination with BCG on children from tuberculous families. JAMA. 101:1933;1619-1626.
79. Aronson J D. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc. 58:1948;255-281.
80. Selter H. Ueber die Bedeutung der Calmetteschen Schutzimpfunf gegen Tuberculose. Dsch med Wschr. 43:1928;1803-1805.
81. Lange B. Die calmettesche schutzimpfung und die sauglingserkrankungen in Lübeck. Dtsch med Wschr. 56:1930;927-929.
82. Lignières J. Discussion before the Academy of Medicine on the value of the BCG vaccine. JAMA. XC:1928;1884.
83. Kraus R. Zurfrage der zulässigkeit der präventiven schutzimpfung gegen tuberkulose nach Calmette. Wien Klin Wschr. 48:1927;1508-1510.
84. Dreyer G, Vollum R. Mutations and pathogenicity, experiments with BCG. Lancet. 1:1931;9-15.
85. Korshun S W, Dwijkow P P, Gorochochownikowa A J. Zur frage der virulenzhöhung der kultur BCG. Centralbl f Bakt. 3:1929;297-305.
86. Gerlach F. Die schutzimpfung gegen tuberkulose mit BCG nach Calmette-Guérin. Ergebn d Hyg Bakt Immunitäts forsch u exper Therap. 11:1930;775-886.
87. Birkhaug K. Protection against tuberculosis with BCG vaccine in guinea pigs. Ann Inst Past. XLIX:1932;630-652.
88. Lignières J. Nouvelle contribution á l'etude des propriétés pathogènes du vaccin BCG et son application à la prophylaxie de la tuberculose. Bull Acad Med (Paris 3me série). XCIX:1928;512.
89. Wallgren A. Intradermal vaccination with BCG virus. JAMA. 91:1928;1876-1881.
90. Wallgren A. Résultats de la vaccination intracutanée contre la tuberculose au moyen du BCG. Ann Inst Pasteur. 1:1929;799-808.
91. Petroff S A. A new analysis of the value and safety of protective immunization with BCG (Bacillus Calmette Guérin). Am Rev Tuberc. 20:1929;275-296.
92. Gerlach F, Kraus R. Tuberkuloseschutzimpfung mit BCG bei affen. Ztsch f Immunitätsf. IX:1928;306-318.
93. Irvine K N. The BCG vaccine. 1934;Oxford Univ Press, London.
94. Irvine K N. BCG. Vaccination in theory and practice. 1949;Blackwell Sci Pub, Oxford.
95. Rosenthal S R. Dissociation and variation of virulence or attenuation. Chapter 5. Rosenthal S R. BCG vaccination against tuberculosis: 1957;70 Little, Brown and Co, Boston.
96. Crispen R. BCG vaccine in perspective. Sem Oncol. 1:1974;311-317.
97. Watson E A. Studies on bacillus Calmette-Guérin (BCG) and vaccination against tuberculosis. Can J Med Res. 9:1933;128.
98. Kraus R. Ueber die Abschwächung der tuberkulogenen Eigenschaften des BCG-Stammes. Ztsch f Immunitätsf. 60:1929;463-469.
99. Saenz A. Deep broth culture of BCG. Lancet. II:1931;1406-1407.
100. Gheorghiu M, Lagrange P H, Fillastre C. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J Biol Stand. 16:1988;15-26.
101. Hart P D, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J. 30:1977;293-295.
102. Bjartveit K, Waaler H. Some evidence of the efficacy of mass BCG vaccination. Bull WHO. 33:1965;289-319.
103. Zhang Y, Wallace R J Jr, Mazurek G H. Genetic differences between BCG substrains. Tubercle Lung Dis. 76:1995;43-50.
104. Behr M A, Small P M. Has BCG attenuated to impotence. Nature. 389:1997;133-134.
105. Behr, M, A, Wilson, M, A, Gill, W, P, Comparative genomics of BCG vaccines using a DNA-microarray. Tuberculosis vaccine development and evaluation. 26-28 August 1998, San Francisco, CA: 48.
106. Stover C K, de la Cruz V F, Fuerst T R. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.
107. Andersen P. Effective vaccination of mice infected against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun. 62:1994;2536-2544.
108. Horwitz M A, Byong-Wha E L, Dillon B J, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Sci USA. 92:1995;1530-1534.
109. Huygen K, Content J, Dewnis O. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2:1996;893-899.
110. Tascon R E, Colston M J, Ragno S, Stavropoulos E, Gregory D, Lowrie D B. Genetic vaccination against tuberculosis by DNA injection. Nature Med. 2:1996;888-893.